Latest news

• Surging sales of Lundbeck's CNS drugs assist recovery

  Since its former blockbuster Cipralex (escitalopram) started to succumb to generic competition, Lundbeck has looked to two newer antidepressants - Brintellix/Trintellix (vortioxetine) and Rexulti (brexpiprazole) - to step in and fill the

• Lundbeck to cut 1,000 jobs in major restructure

  sales from drugs such as depression treatment Cipralex (escitalopram).

• US filing aims to elevate Brintellix above its competition

  Brintellix has been on the market in the US since 2013 and has been positioned as a successor to its older antidepressant Cipralex (escitalopram), which was selling around $2bn a year

• Lundbeck and Otsuka's Rexulti set for August launch in US

  which it hopes will restore growth after the loss of patent protection on US blockbuster antidepressant Lexapro/Celexa (escitalopram).

• Schultz takes Lundbeck helm after leaving Novo Nordisk

  to continued generic competition to Alzheimer's therapy Ebixa (memantine) and antidepressant Cipralex (escitalopram).